Authors:
ICLI F
CAY F
DINCOL D
KARAOGUZ H
DEMIRKAZIK A
AKBULUT H
Citation: F. Icli et al., PROGNOSTIC FACTORS IN PATIENTS WITH RECURRENT BREAST-CANCER FOLLOWINGMASTECTOMY, European journal of cancer, 34, 1998, pp. 500-500
Authors:
CAY F
ONAT H
SAIP P
KARS A
DEMIRKAZIK A
AKBULUT H
KOCA S
AKYOL F
AKTAN G
FIRAT D
Citation: F. Cay et al., CISPLATIN AND EPIRUBICIN INDUCTION CHEMOTHERAPY FOLLOWED BY CHEMORADIOTHERAPY IN LIMITED STAGE SMALL-CELL LUNG-CANCER (LS-SCLC), Annals of oncology, 9, 1998, pp. 502-502
Authors:
DEMIRKAZIK A
ONAT H
SAIP P
OZGUROGLU M
KARS A
CAY F
DEMIR G
UNER A
ARPACI F
AKTAN G
Citation: A. Demirkazik et al., HIGH-DOSE EPIRUBICIN AND CISPLATIN INDUCTION CHEMOTHERAPY SEQUENTIALLY FOLLOWED BY IFOSFAMIDE AND ETOPOSIDE CHEMOTHERAPY IN EXTENSIVE-STAGESMALL-CELL LUNG-CANCER (ES-SCLC), Annals of oncology, 9, 1998, pp. 505-505
Authors:
ARICAN A
DINCOL D
AKBULUT H
CAY F
ICLI F
KARAOGUZ H
DEMIRKAZIK A
Citation: A. Arican et al., SURGICAL RESECTION FOLLOWED BY ADJUVANT CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER WITH LIMITED DISEASE, Annals of oncology, 9, 1998, pp. 509-509
Authors:
DINCOL D
ARICAN A
AYDIN F
SAMUR M
WILLKE A
AKBULUT H
PAMIR A
CAY F
ICLI F
Citation: D. Dincol et al., A COMPARISON OF IMIPENEM MONOTHERAPY VERSUS CEFOPERAZONE SULBACTAM PLUS AMIKACIN COMBINATION TREATMENT IN FEBRILE NEUTROPENIC CANCER-PATIENTS/, The Cancer journal, 11(2), 1998, pp. 89-93
Authors:
ARICAN A
DINCOL D
SAMUR M
DEMIRKAZLK A
SENCAN O
AKBULUT H
KARAOGUZ H
CAY F
ICLI F
Citation: A. Arican et al., COST-EFFECTIVENESS OF RADIONUCLIDE BONE SCANNING TO RULE OUT ASYMPTOMATIC BONE METASTASES IN CLINICALLY OPERABLE NONSMALL CELL LUNG-CANCER, European journal of cancer, 33, 1997, pp. 4-4
Authors:
DINCOL D
ARICAN A
AYDIN F
SAMUR M
WILLKE A
AKBULUT H
PAMIR A
CAY F
ICLI F
Citation: D. Dincol et al., COMPARATIVE-STUDY OF IMIPENEM VERSUS SULPERAZONE PLUS AMIKACIN IN FEBRILE NEUTROPENIA, European journal of cancer, 33, 1997, pp. 253-253
Citation: F. Cay et C. Chassapis, AN IT VIEW ON PERSPECTIVES OF COMPUTER-AIDED PROCESS PLANNING RESEARCH, Computers in industry, 34(3), 1997, pp. 307-337
Authors:
DINCOL D
AKBULUT H
ICLI F
SAMUR M
KARAOGUZ H
DEMIRKAZIK A
CAY F
Citation: D. Dincol et al., RESULTS OF THE CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISOLONE (CHOP)+ -BLEOMYCIN TREATMENT AND EVALUATION OF PROGNOSTIC FACTORS IN AGGRESSIVE LYMPHOMAS IN TURKEY/, Oncology, 54(5), 1997, pp. 376-379
Authors:
ICLI F
KARAOGUZ H
AKBULUT H
DINCOL D
DEMIRKAZIK A
CAY F
Citation: F. Icli et al., PHASE-II STUDY OF A MODIFIED COMBINATION OF ETOPOSIDE, DOXORUBICIN, AND CISPLATIN FOR PATIENTS WITH ADVANCED GASTRIC, Journal of surgical oncology, 64(4), 1997, pp. 318-323
Authors:
DINCOL D
ICLI F
AKBULUT H
SAMUR M
KARAOGUZ H
DEMIRKAZIK A
CAY F
Citation: D. Dincol et al., RESULTS OF THE CYCLOPHOSPHAMIDE, ADRIAMYCINE, VINCRISTINE, PREDNISOLON (CHOP) + - BLEOMYCINE TREATMENT AND EVALUATION OF PROGNOSTIC FACTORSIN AGGRESSIVE LYMPHOMAS/, European journal of cancer, 31A, 1995, pp. 784-784
Authors:
DINCOL D
ICLI F
KARAOGUZ H
CAY F
ARICAN A
DEMIRKAZIK A
AKBULUT H
Citation: D. Dincol et al., MESNA IFOSFAMIDE, MITOXANTRONE, ETOPOSIDE, BLEOMYCIN, VINCRISTINE, PREDNISONE (MINE-BOP) COMBINATION CHEMOTHERAPY IN THE TREATMENT OF REFRACTORY AND RELAPSED NON-HODGKINS-LYMPHOMA, Acta oncologica, 34(7), 1995, pp. 937-940